Bisphosphonate-Related Osteonecrosis of the Jaw: Is pH the Missing Part in the Pathogenesis Puzzle?

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 5, 2010, Pages 1158-1161

  Otto, Sven ^a   Hafner, Sigurd ^a   Mast, Gerson ^a   Tischer, Thomas ^b   Volkmer, Elias ^c   Schieker, Matthias ^c   Stürzenbaum, Stephen R ^d   von Tresckow, Emmo ^e   Kolk, Andreas ^b   Ehrenfeld, Michael ^a   Pautke, Christoph ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ACIDOSIS; ARTICLE; BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW; BONE; BONE METASTASIS; BONE NECROSIS; BONE REMODELING; CANCER CHEMOTHERAPY; CANCER PATIENT; CIGARETTE SMOKING; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG USE; HEAD AND NECK CANCER; HUMAN; INFECTION; IRRADIATION; JAW; JAW OSTEONECROSIS; MOUTH HYGIENE; PATHOGENESIS; PH; RISK FACTOR; WOUND HEALING;

ACIDOSIS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; HYDROGEN-ION CONCENTRATION; JAW; JAW DISEASES; OSTEONECROSIS; RISK FACTORS;

EID: 77950809933     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.07.079     Document Type: Article

References (46)

1. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
2. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 (2003) 4253
3. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104
4. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
5. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479
6. Abu-Id M.H., Warnke P.H., Gottschalk J., et al. "Bis-phossy jaws"-High and low-risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36 (2008) 95
7. Hess L.M., Jeter J.M., Benham-Hutchins M., and Alberts D.S. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121 (2008) 475
8. Yarom N., Yahalom R., Shoshani Y., et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18 (2007) 1363
9. King A.E., and Umland E.M. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 28 (2008) 667
10. Rizzoli R., Burlet N., Cahall D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42 (2008) 841
11. Gertz B.J., Holland S.D., Kline W.F., et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58 (1995) 288
12. Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719
13. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397
14. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580
15. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968
16. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
17. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 (2008) 826
18. Wessel J.H., Dodson T.B., and Zavras A.I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg 66 (2008) 625
19. Dimopoulos M.A., Kastritis E., Bamia C., et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20 (2009) 117
20. Badros A., Terpos E., Katodritou E., et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26 (2008) 5904
21. McDonald M.M., Dulai S., Godfrey C., et al. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 43 (2008) 653
22. Orriss I.R., Key M.L., Colston K.W., and Arnett T.R. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106 (2009) 109
23. Walter C., Klein M.O., Pabst A., et al. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14 (2010) 35
24. Vignery A., and Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec 196 (1980) 191
25. Garetto L.P., and Tricker N.D. Remodeling of bone surrounding the implant interface. In: Garetto L.P., Turner C.H., Duncan R.L., and Burr D.B. (Eds). Bridging the Gap Between Dental and Orthopaedic Implants. Third Annual Indiana Conference, Indianapolis, IN (1998) 89-100
26. Huja S.S., Fernandez S.A., Hill K.J., and Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 288 (2006) 1243
27. Bauss F., Pfister T., and Papapoulos S. Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 26 (2008) 406
28. Wolf A.M., Rumpold H., Tilg H., et al. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 91 (2006) 1165
29. Roelofs A.J., Jauhiainen M., Monkkonen H., et al. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144 (2009) 245
30. Hansen T., Kunkel M., Weber A., and James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates-Histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35 (2006) 155
31. Sedghizadeh P.P., Kumar S.K., Gorur A., et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66 (2008) 767
32. Scavelli C., Di Pietro G., Cirulli T., et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 6 (2007) 3256
33. Deckers M.M., Van Beek E.R., Van Der Pluijm G., et al. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 17 (2002) 998
34. Cetinkaya B.O., Keles G.C., Ayas B., and Gurgor P. Effects of risedronate on alveolar bone loss and angiogenesis: A stereologic study in rats. J Periodontol 79 (2008) 1950
35. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318
36. Sonis S.T., Elting L.S., Keefe D., et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 (2004) 1995
37. Landesberg R., Cozin M., Cremers S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66 (2008) 839
38. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
39. Otto S., Hafner S., and Grötz K.A. The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67 (2009) 589
40. Russell R.G., Watts N.B., Ebetino F.H., and Rogers M.J. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19 (2008) 733
41. Sato M., Grasser W., Endo N., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095
42. 2, pH, and redox potential of experimental abscesses. Proc Soc Exp Biol Med 147 (1974) 29
43. Bertram P., Treutner K.H., Klosterhalfen B., et al. (Artificial pressure increase in subcutaneous abscess with evidence of general systemic reaction). Langenbecks Arch Chir 382 (1997) 291
44. Wiese K.G. (Electrolyte concentration, real and osmotic pressure in abscesses). Zentralbl Chir 119 (1994) 54
45. Nancollas G.H., Tang R., Phipps R.J., et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38 (2006) 617
46. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961